Inflammatory Bowel Disease Biomarkers Consortium (IBD BIOM)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Irritable Bowel Disease
  • Location: Europe


The Inflammatory Bowel Disease Biomarkers Consortium (IBD-BIOM) addresses the need to improve  understanding of inflammatory bowel disease (IBD) through new biomarkers into molecular dysfunctions that give rise to IBD. The targeted biomarkers will be translated into early-detection clinical diagnostic tests for IBD patients.


IBD-BIOM aims to advance the development of early warning diagnostics and molecular biomarker discovery for IBD using integrated “–omics” technologies. The aim is to discover reliable biomarkers that could allow insights into the molecular pathogenesis of IBD and development of prognostic tools and targeted therapies.

IBD-BIOM aims to discover clinical biomarkers for IBD to (a) enable the early diagnosis of patients with IBD and (b) point to possible molecular targets for new, improved therapies to alleviate the suffering of IBD patients.


IBD-BIOM is funded by the European Union through the Seventh Framework Programme (Reference: 305676).


Sponsors & Partners

Cedars Sinai Medical Center

Genos Ltd (Croatia)

IP Research Consulting SAS (France)

Leiden University Medical Center (Netherlands)

Ludger Ltd (UK)

Max Planck Institute (Berlin)

University Hospital Careggi (Florence)

University of Edinburgh

University of Zagreb (Croatia)

Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.